Clin Osteol 2016; 21(1): 10-17

Sklerostin při chronickém onemocnění a selhání ledvin: literární přehled současných poznatkůReview articles

E. Vykoukalová, S. Dusilová Sulková, R. Šafránek, J. Vávrová, M. Kalousová, J. Kohoutová, A. Malá, M. Ryba, L. Pavlíková, V. Palička

Sclerostin has nega porosis. Chronic kidney disease (CKD) is associated with calcium, phosphorus and vitamin D metabolism disorders and it is obligatory con­ nected with renal osteopathy and cardiovascular system disorders (chronic kidney disease - mineral and bone disorder, CKD-MBD). According to recen cular cross-talk). Serum sclerostin concentration increases in the course of chronic kidney disease. Not only missing renal elimination, but also bone metabolism change, i.e. sclerostin secretion change, could be the reason. Contrary to the expectations, correlation between bone den­ sity and sclerostin serum concentration is rather positive than negative, which can also show a change between sclerostin secretion and elimination in CKD patients. Inverse correlation between parathormone and sclerostin is preserved in CKD patients, even those with end stage re se patients. The prognostic relevance of sclerostin is intensively studied in CKD patients, especially those on long-term maintenance haemodialy­ sis (HD). Some recent studies show, that high sclerostin levels in HD patients predict lower cardiovascular mortality of these patients. Rather h ve this. The goal of this article is to summarize previous knowledge about sclerostin, especially in CKD and HD patients. #FOOTER#:10 Osteologický bulletin 2016 č. 1 roč. 21 #HEADER#:PŘEHLEDOVÝ ČLÁNEK

Keywords: Sclerostin, Osteoporosis, Chronic kidney di cation, Cardiovascular mortality, Sclerostin antibody

Published: June 11, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Vykoukalová E, Dusilová Sulková S, Šafránek R, Vávrová J, Kalousová M, Kohoutová J, et al.. Sklerostin při chronickém onemocnění a selhání ledvin: literární přehled současných poznatků. Osteologický bulletin. 2016;21(1):10-17.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Moester MJC, Papapoulos SE, Lowik CWG et al. Sclerostin and future perspectives. Calcif Tissue Int 2010;87:99-107. Go to original source...
    2. van Bezooijen RL, ten Dijke P, Papapoulos SE et al. SOST/sclerostin, an te-derived negative regulator of bone formation. Cytokine Growth Factor Rev 2005;16:319-327. Go to original source...
    3. Pelletier S, Confavreux CB, Haesebaert J, Guebre-Egziabher F, Bacchetta Carlier C, Chardon L, Laville M, Chapurlat R, London GM, Lafage-Proust MH, Fouque D. Serum sclerostin: the missing link in the bone-vessel cross-talk un emodialysis patients? Osteoporosis Int 2015;26:2165-2174. Go to original source...
    4. Brandenburg VM, Kramann R, Koos R, Kruger T, Schurgers L, Muhlenbruch G, Hubner S, Gladziwa U, Drechsler Ch, Ketteler M. Relationship between scleros­ tin and cardiovascular calcification in hemodialysis patients: a cross-sectiona dy. BMC Nephrol 2013;14:219. Go to original source...
    5. Kirkpantur A, Balci M, Turkvatan A, Afsar B. Independent association between serum sclerostin levels and carotid artery atherosclerosis in prevalent haemodia sis patients.Clin Kidney J 2015;8(6):737-743. Go to original source...
    6. McNulty M, Singh RJ, Li X, Bergstralh EJ, Kumar R. Determination of serum and plasma sclerostin concantrations by enzyme-linked immunoassays. J Clin Endocrinol Metab 2011;96:E1159-1162. Go to original source...
    7. Amrein K, Drexler C, Dimai HP, Dobnig H, Pfeifer K, Tomaschity A, Pieber Tr, Fahrleitner-J^mmer A Sclerostin and its association with physical activity, age, gender, body composition, and bone mineral content in healthy adults. J Clin Endocrinol Metab 2012;97(1):148-154. Go to original source...
    8. Battaglino RA, Sudhakar S, Lazzari AA, Garshick E, Zafonte R, Morse LR. Circulating sclerostin is elevated in short-term and reduced in long-term SCI. Bone 2012;52:600-605. Go to original source...
    9. Urano T, Shiraki M, Ouchi Y, Inoue S. Association of circulating sclerostin l with fat mass and metaboolic dinase-related markers in Japanese postmenopausal women. J Clin Endocrinol Metab 2012;97(8):E1473-1477. Go to original source...
    10. Modder Ul, Hoey KA, Amin S, McCready LK, Achenbach Sj, Riggs BL et al. Relation of age, gender, and bone mass to circulating sclerostin levels in women and men. J Bone Miner Res 2011;26:373-379. Go to original source...
    11. Ardawi MS, Al-Kadi HA, Rouzi AA, Qari MH. Determinant of serum sclerostin in healthy pre- and postmenopausal women. J Bone Miner Res 2011;97:148-154. Go to original source...
    12. Modder Ul, Clowes JA, Hoey K, Peterson JM, McCready, Oursler MJ et al. Regulation of circulating sclerostin levels by sex steroids in women and in men. J Bone Miner Res 2011;26:27-34. Go to original source...
    13. Malluche HH, Davenport DL, Cantor T, Monier-Faugere MC. Bone mineral den­ sity and serum biochemical predictors of bone loss in patients with CKD on dia­ lysis. Clin J Am Soc Nephrol 2014; 9:1254-1262. Go to original source...
    14. Pblletier S, Dubourg L, Carlier MC, Hadj-Aissa A, Fouque D. The relation bet en renal function and serum sclerostin in adult patiens with CKD. Clin J Am Soc Nephrol 2013;8:819-823. Go to original source...
    15. Bonani M, Rodriguez D, Fehr T, Mohebbi N, Brockmann J, Blum M, Graf N, Fry D, Wuthrich RP. Sclerostin blood levels before and after kidney transplanta­ tion. Kidney Blood Press Res 2014;39:230-239. Go to original source...
    16. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH. Effect of para­ thyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434-1441. Go to original source...
    17. Yu EW, Kumbhani R, Siwila-Sackman E, Leder BZ. Acute Decline in Serum Sclerostin in Response to PTH Infusion in Healthy Men. J Clin Endocrinol Metab 2011;96(11):E1848-E1851. Go to original source...
    18. Belido T, Ali AA, Gubrij I, Plotkin LI, Fu Q, O Brien CA, Manolagas SC, Jilka RL. Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology 2005;146:4577-4583. Go to original source...
    19. Silvestrini G, Ballanti P, Leopizzi M, Sebastiani M, Berni S, Di Vito M, Bon E. Effects of intermittent parathyroid hormone (PTH) administration on SOST mRNA and protein in rat bone. J Mol Histol 2007;38:261-269. Go to original source...
    20. Drake MT, Srinivasan B, Modder Ul, Peterson JM, McCready LK, Riggs BL et al. Effects of parathyroid hormone treatment on circulating sclerostin levels in po menopausal women. J Clin Endocrinol Metab 2010;95:5056-5062. Go to original source...
    21. van Lierop AH, Witteveen JE, Hamdy NA, Papapoulos SE. Patients with primary hyperparathyroidism have lower circulating sclerostin levels than euparathyroid controls. Eur J Endocrinol 2010;163:833-837. Go to original source...
    22. Ardawi MS, AJ-Sibiany AM, Bakhsh TM, Rouzi AA, Qari MH. Decreased serum sclerostin levels in patients with primary hyperparathyroidis and a longitudinal study. Osteoporosis Int 2012;23:1789-1797. Go to original source...
    23. Costa AG, Cremers S, Rubin MR, McMahon DJ, Sliney Jr. J, Lazaretti-Castro M et al. Circulating sclerostin in di Endocrinol Metab 2011;96:3804-3810. Go to original source...
    24. Garnero P, Somay-Rendu E, Munoz F, Borel O, Chapurlat RD. Association of se­ rum sclerostin with bone mineral density, bone turnover, steroid and hormons, and fracture risk in postmenopausal women: the OFFELY study. Osteoporos Int 2013;24:489^94. Go to original source...
    25. Ishimura E, Okuno S, Ichii M, Norimine K, Yamakawa T, Shoji S, Nishizawa Inaba M. Relationship between serum sclerostin, bone metabolism markers, and bone mineral density in maintenance hemodialysis patients. J Clin Endocrinol Metab 2014;99:4315 4320. Go to original source...
    26. Cejka D, Herberth J, Branscum AJ, Fardo DW, Monier-Faugere MC, Diarra D, Haas M, Malluche HH. Sclerostin and Dickkopf-1 in renal osteodystrophy. Clin J Am Soc Nephrol 2011; 6:877-882. Go to original source...
    27. Yang CY, Chang ZF, Chau YP, Chen A, Yang WC, Yang AH, Lee OK. Circu­ lating Wnt/p-catenin signalling inhibitors Nephrol Dial Transplant 2015; 30:1356-1363. Go to original source...
    28. Drechsler Ch, Evenepoel P, Vervloet M, Wanner Ch, Ketteler M, Marx N, Flo J, Dekker FW, Brandenburg VM. High levels of circulating sclerostin are asso­ ciated with better cardiovascular survival in incident dialysis patients: results the NECOSAD study. Nephrol Dial Transplant 2015;30:288-293. Go to original source...
    29. Nowak A, Artunc F, Serra AL, Pollock E, Krayenbuhl PA, Muller Ch, Friedrich B. Sclerostin Quo Vadis? - is this a useful long-term mortality parameter in pre­ valent hemodialysis patients? Kidney Blood Press Res 2015;40:266-276. Go to original source...
    30. Arasu A, Cawthon PM, Lui LY, Do TP, Arora PS, Cauley JA et al. Serum scle­ rostin and risk ofhip fracture in older Caucasian women. J Clin Endocrinol Metab 2012;97:2027-2032. Go to original source...
    31. Ardawi MS, Rouzi AA, Al-Sibiani SA, Al-Senani NS, Qari MH, Mousa SA High serum sclerostin predicts the occurance of osteoporotic fractures in postmenopau­ sal women: the Center of Excellence for Osteoporosis Research Study. J Bone Miner Res 2012;27:2592-2602.
    32. Cejka D, Jäger-Lansky A, Kiewig H et al. Sclerostin serum levels correlate po tively with bone mineral density and microarchitecture in haemodialysis patients. Nephrol Dial Transplant 2012;27:226-230. Go to original source...
    33. de Oliveira RA, Barreto FC, Mendes M, dos Reis LM, Castro JH, Britto ZML, Marques IDB, Carvalho AB, Moysés RM, Jorgetti V. Peritoneal dialysis per se is a risk factor for sclerostin-associated adynamic bone disease. Kidney Int 2015; 87:1039-1045. Go to original source...
    34. Yhu D, Mackenyie NC, Millan JL, Farquharson C, MacRae VE. The appearance and modulation of osteocyte marker expression during calcification of vascular smooth muscle cells. PloS One 2011;6:e19595. Go to original source...
    35. Moss DW, Eaton RH, Smith JK, Whitby LG. Association of inorganic pyro­ phosphatase activity with human alkaline phosphatase preparations. Biochem J 1967;102:53-57.
    36. Qureshi AR, Olauson H, Witasp A, Haarhaus M, Brandenburg V, Wernerson A, Lindholm B, Soderberg M, Wennberg L, Nordfors L, Ripsweden J, Barany P, Stenvinkel P: Increased circulating sclerostin levels in end-stage renal disease p dict biopsy-verified vascular medial calcification and coronary artery calcifica­ tion. Kidney Int 2015;88:1356-1364. Go to original source...
    37. Viaene L, Behets GJ, Claes, Meijers B, Blocki F, Brandenburg V, Evenepoel P, D Haese PC. Sclerostin: another bone-related protein related to all-cause mortali­ ty in haemodialysis?. Nephrol Dial Transplant 2013;28:3024-3030. Go to original source...
    38. Moe S, Drueke T, Cunningham J et al. Definition, evaluation, and classif of renal osteodystrophy: A position statement from Kidney Disease: Improving Global Outcome (KDIGO). Kidney Int 2006;69:1945-1953. Go to original source...
    39. Goncalves FLC, Elias RM, dos Reis LM, Graciolli FG, Zampieri FG, Oliveira Jorgetti V, Moysés RMA Serum sclerostin is an independent predictor of morta­ lity in hemodialysis patients. BMC Nephrol 2014;15:190. Go to original source...
    40. Desmond P, Jang G, Stouch B, Fang L, Posvar E. Single-dose, placebo-controll randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res 2011;26:19-26. Go to original source...
    41. Moe SM, Chen NX, Nexman CL, Organ JM, Kneissel M, Kramer I, Gattone VH, Allen MR. Anti-sclerostin antipody treatment in a rat model of progressive renal osteodystrophy. J Bone Miner Res 2015;30:499-509. Go to original source...
    42. Drueke TB, Lafage-Proust MH: Sclerostin: just one more player in renal bone disease? Clin J Am Soc Nephrol 2011;6:700-703. Go to original source...

    Return to the content


    Clinical Osteology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.